1-15 of 301
Optimizing Screening Pathways for Alpha-1 Antitrypsin Deficiency
Clinician's RoundtableOptimizing Screening Pathways for Alpha-1 Antitrypsin Deficiency
Alexandria May, PharmD, BCPS
Michael Czarnecki, MD
How to Increase Testing Rates for Alpha-1 Antitrypsin Deficiency
Clinician's RoundtableHow to Increase Testing Rates for Alpha-1 Antitrypsin Deficiency
Brian P. McDonough, MD, FAAFP
Brooks Kuhn, MD, MAS
Decoding epNECs: Diagnostic Challenges and Emerging Strategies
Project Oncology®Decoding epNECs: Diagnostic Challenges and Emerging Strategies
Brian P. McDonough, MD, FAAFP
Andrew E. Hendifar, MD
Key Differences in Pulmonary and Extrapulmonary NEC Management
Project Oncology®Key Differences in Pulmonary and Extrapulmonary NEC Management
Alexandria May, PharmD, BCPS
Lowell B. Anthony, MD, FACP
Advancing Management of Extrapulmonary NEC: The Emerging Role of DLL3
Project Oncology®Advancing Management of Extrapulmonary NEC: The Emerging Role of DLL3
Charles Turck, PharmD, BCPS, BCCCP
Rohit Thummalapalli, MD
Evolving epNEC Care: From Default Regimens to Precision-Driven Strategies
Project Oncology®Evolving epNEC Care: From Default Regimens to Precision-Driven Strategies
Alexandria May, PharmD, BCPS
Chandrikha Chandrasekharan, MBBS
- advertisement
Spotting the Warning Signs of Subarachnoid Hemorrhage
NeuroFrontiersSpotting the Warning Signs of Subarachnoid Hemorrhage
Jay Max Findlay
The Critical Next Steps After Subarachnoid Hemorrhage Diagnosis
NeuroFrontiersThe Critical Next Steps After Subarachnoid Hemorrhage Diagnosis
Jay Max Findlay
The Recovery Trajectory of Subarachnoid Hemorrhage
NeuroFrontiersThe Recovery Trajectory of Subarachnoid Hemorrhage
Jay Max Findlay
Evaluating Delayed Presentations of Subarachnoid Hemorrhage
NeuroFrontiersEvaluating Delayed Presentations of Subarachnoid Hemorrhage
Jay Max Findlay
The Limits of Traditional AFib Prediction Models in ATTR-CA
Heart MattersThe Limits of Traditional AFib Prediction Models in ATTR-CA
Quality of Life Conversations in ATTR-CM Care
Heart MattersQuality of Life Conversations in ATTR-CM Care
Kevin S. Shah, MD
- advertisement
How KIT D816V Shapes Systemic Mastocytosis Diagnosis and Treatment
Clinician's RoundtableHow KIT D816V Shapes Systemic Mastocytosis Diagnosis and Treatment
Brian P. McDonough, MD, FAAFP
Thanai Pongdee, MD
Survival Outcomes in Squamous Cell Carcinoma of the Anal Canal: POD1UM-303 Data
Project Oncology®Survival Outcomes in Squamous Cell Carcinoma of the Anal Canal: POD1UM-303 Data
Brian P. McDonough, MD, FAAFP
Stacey Cohen, MD
Optimizing cGVHD Treatment Decisions in the Second- and Third-Line Settings
Project Oncology®Optimizing cGVHD Treatment Decisions in the Second- and Third-Line Settings
Charles Turck, PharmD, BCPS, BCCCP
Stephanie Gregory, CNP
